Efficacy and safety of PG201 (Layla®) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study

Wan Hee Yoo, Han Gyul Yoo, Sung Hwan Park, Han joo Baek, Yun Jong Lee, Seung Cheol Shim, Seong Wook Kang, Hyun Ah Kim, Jung Soo Song, Chang Hee Suh, Sungjae Choi, Bo Young Yoon, Dong Nyeon Tae, Hyun Sook Ko, Yeong Wook Song

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The objectives of the study are to demonstrate the non-inferiority of PG201 (Layla®) 600 mg in comparison with celecoxib 200 mg for the treatment of symptomatic knee osteoarthritis (OA). In total, 309 patients were randomly assigned to receive either the test drug, PG201 600 mg (n = 154) or celecoxib 200 mg (n = 155). The primary efficacy variable was improvement in mean 100-mm pain VAS score from baseline to the final visit (week 8), and this value was compared between the 2 treatment groups. Secondary outcome variables included changes from baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain VAS score and subscale score, patient’s global assessment of disease status quality of life (short form-36) and responder index at weeks 4 and 8. For safety assessment, adverse events were recorded at each clinical visit. At weeks 8, the 100-mm pain VAS scores were significantly decreased in patients receiving both PG201 600 mg (p < 0.0001) and celecoxib 200 mg (p < 0.0001) as compared to the baseline scores; however, no statistically significant differences in these values were noted between the groups (p = 0.312). These results met pre-specified criteria for non-inferiority for both the intent-to-treat and per-protocol populations. PG201 600 mg and celecoxib 200 mg were both well tolerated and no statistically significant differences in the tolerability profile between the groups. PG201 600 mg was as effective and safe as celecoxib 200 mg in the treatment of symptomatic knee OA and might be a useful new medication for the treatment of symptomatic knee OA.

Original languageEnglish
Pages (from-to)1369-1378
Number of pages10
JournalRheumatology International
Volume34
Issue number10
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Celecoxib
Knee Osteoarthritis
Safety
Pharmaceutical Preparations
Pain
Therapeutics
Ontario
Arthritis
Quality of Life
herbal extract PG201

Keywords

  • Celecoxib
  • Knee osteoarthritis
  • PG201

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Efficacy and safety of PG201 (Layla®) and celecoxib in the treatment of symptomatic knee osteoarthritis : a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study. / Yoo, Wan Hee; Yoo, Han Gyul; Park, Sung Hwan; Baek, Han joo; Lee, Yun Jong; Shim, Seung Cheol; Kang, Seong Wook; Kim, Hyun Ah; Song, Jung Soo; Suh, Chang Hee; Choi, Sungjae; Yoon, Bo Young; Tae, Dong Nyeon; Ko, Hyun Sook; Song, Yeong Wook.

In: Rheumatology International, Vol. 34, No. 10, 01.01.2014, p. 1369-1378.

Research output: Contribution to journalArticle

Yoo, Wan Hee ; Yoo, Han Gyul ; Park, Sung Hwan ; Baek, Han joo ; Lee, Yun Jong ; Shim, Seung Cheol ; Kang, Seong Wook ; Kim, Hyun Ah ; Song, Jung Soo ; Suh, Chang Hee ; Choi, Sungjae ; Yoon, Bo Young ; Tae, Dong Nyeon ; Ko, Hyun Sook ; Song, Yeong Wook. / Efficacy and safety of PG201 (Layla®) and celecoxib in the treatment of symptomatic knee osteoarthritis : a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study. In: Rheumatology International. 2014 ; Vol. 34, No. 10. pp. 1369-1378.
@article{98053043e8f941618fc12d15d79b0006,
title = "Efficacy and safety of PG201 (Layla{\circledR}) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study",
abstract = "The objectives of the study are to demonstrate the non-inferiority of PG201 (Layla{\circledR}) 600 mg in comparison with celecoxib 200 mg for the treatment of symptomatic knee osteoarthritis (OA). In total, 309 patients were randomly assigned to receive either the test drug, PG201 600 mg (n = 154) or celecoxib 200 mg (n = 155). The primary efficacy variable was improvement in mean 100-mm pain VAS score from baseline to the final visit (week 8), and this value was compared between the 2 treatment groups. Secondary outcome variables included changes from baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain VAS score and subscale score, patient’s global assessment of disease status quality of life (short form-36) and responder index at weeks 4 and 8. For safety assessment, adverse events were recorded at each clinical visit. At weeks 8, the 100-mm pain VAS scores were significantly decreased in patients receiving both PG201 600 mg (p < 0.0001) and celecoxib 200 mg (p < 0.0001) as compared to the baseline scores; however, no statistically significant differences in these values were noted between the groups (p = 0.312). These results met pre-specified criteria for non-inferiority for both the intent-to-treat and per-protocol populations. PG201 600 mg and celecoxib 200 mg were both well tolerated and no statistically significant differences in the tolerability profile between the groups. PG201 600 mg was as effective and safe as celecoxib 200 mg in the treatment of symptomatic knee OA and might be a useful new medication for the treatment of symptomatic knee OA.",
keywords = "Celecoxib, Knee osteoarthritis, PG201",
author = "Yoo, {Wan Hee} and Yoo, {Han Gyul} and Park, {Sung Hwan} and Baek, {Han joo} and Lee, {Yun Jong} and Shim, {Seung Cheol} and Kang, {Seong Wook} and Kim, {Hyun Ah} and Song, {Jung Soo} and Suh, {Chang Hee} and Sungjae Choi and Yoon, {Bo Young} and Tae, {Dong Nyeon} and Ko, {Hyun Sook} and Song, {Yeong Wook}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00296-014-2964-8",
language = "English",
volume = "34",
pages = "1369--1378",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Efficacy and safety of PG201 (Layla®) and celecoxib in the treatment of symptomatic knee osteoarthritis

T2 - a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study

AU - Yoo, Wan Hee

AU - Yoo, Han Gyul

AU - Park, Sung Hwan

AU - Baek, Han joo

AU - Lee, Yun Jong

AU - Shim, Seung Cheol

AU - Kang, Seong Wook

AU - Kim, Hyun Ah

AU - Song, Jung Soo

AU - Suh, Chang Hee

AU - Choi, Sungjae

AU - Yoon, Bo Young

AU - Tae, Dong Nyeon

AU - Ko, Hyun Sook

AU - Song, Yeong Wook

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The objectives of the study are to demonstrate the non-inferiority of PG201 (Layla®) 600 mg in comparison with celecoxib 200 mg for the treatment of symptomatic knee osteoarthritis (OA). In total, 309 patients were randomly assigned to receive either the test drug, PG201 600 mg (n = 154) or celecoxib 200 mg (n = 155). The primary efficacy variable was improvement in mean 100-mm pain VAS score from baseline to the final visit (week 8), and this value was compared between the 2 treatment groups. Secondary outcome variables included changes from baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain VAS score and subscale score, patient’s global assessment of disease status quality of life (short form-36) and responder index at weeks 4 and 8. For safety assessment, adverse events were recorded at each clinical visit. At weeks 8, the 100-mm pain VAS scores were significantly decreased in patients receiving both PG201 600 mg (p < 0.0001) and celecoxib 200 mg (p < 0.0001) as compared to the baseline scores; however, no statistically significant differences in these values were noted between the groups (p = 0.312). These results met pre-specified criteria for non-inferiority for both the intent-to-treat and per-protocol populations. PG201 600 mg and celecoxib 200 mg were both well tolerated and no statistically significant differences in the tolerability profile between the groups. PG201 600 mg was as effective and safe as celecoxib 200 mg in the treatment of symptomatic knee OA and might be a useful new medication for the treatment of symptomatic knee OA.

AB - The objectives of the study are to demonstrate the non-inferiority of PG201 (Layla®) 600 mg in comparison with celecoxib 200 mg for the treatment of symptomatic knee osteoarthritis (OA). In total, 309 patients were randomly assigned to receive either the test drug, PG201 600 mg (n = 154) or celecoxib 200 mg (n = 155). The primary efficacy variable was improvement in mean 100-mm pain VAS score from baseline to the final visit (week 8), and this value was compared between the 2 treatment groups. Secondary outcome variables included changes from baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain VAS score and subscale score, patient’s global assessment of disease status quality of life (short form-36) and responder index at weeks 4 and 8. For safety assessment, adverse events were recorded at each clinical visit. At weeks 8, the 100-mm pain VAS scores were significantly decreased in patients receiving both PG201 600 mg (p < 0.0001) and celecoxib 200 mg (p < 0.0001) as compared to the baseline scores; however, no statistically significant differences in these values were noted between the groups (p = 0.312). These results met pre-specified criteria for non-inferiority for both the intent-to-treat and per-protocol populations. PG201 600 mg and celecoxib 200 mg were both well tolerated and no statistically significant differences in the tolerability profile between the groups. PG201 600 mg was as effective and safe as celecoxib 200 mg in the treatment of symptomatic knee OA and might be a useful new medication for the treatment of symptomatic knee OA.

KW - Celecoxib

KW - Knee osteoarthritis

KW - PG201

UR - http://www.scopus.com/inward/record.url?scp=84918802134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918802134&partnerID=8YFLogxK

U2 - 10.1007/s00296-014-2964-8

DO - 10.1007/s00296-014-2964-8

M3 - Article

C2 - 24531687

AN - SCOPUS:84918802134

VL - 34

SP - 1369

EP - 1378

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 10

ER -